SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS, UTILITY ESTIMATES, RESOURCE UTILISATION, AND COSTS IN CHRONIC IDIOPATHIC URTICARIA

Author(s)

Woods MS1, Zimovetz E1, Beard S1, Balp MM21RTI Health Solutions, Manchester, United Kingdom, 2Novartis Pharma AG, Basel, Switzerland

OBJECTIVES: To systematically identify economic evaluations of treatments recommended for chronic idiopathic urticaria (CIU) and studies reporting health-state utility weights and/or estimates of resource use and costs. METHODS: Systematic searches of MEDLINE, MEDLINE-In-Process, EconLit, EMBASE, the Cochrane Library, and conference abstracts were conducted from 1 January 2000 to 20 December 2011. Inclusion criteria considered studies reporting utility weights, resource use, costs, and/or economic evaluations of treatments in CIU patients older than 12 years. RESULTS: From 266 retrieved records, 3 studies were included: 1 economic evaluation of levocetirizine and 2 cost studies. The economic evaluation was a pooled analysis of two clinical trials comparing levocetirizine with placebo and incorporating productivity losses defined as absenteeism and/or presenteeism. One cost study reported total annual per-patient direct costs of $1,762; the other study reported a cost range between $1,290 and $2,419, depending on disease severity. Cost components included prescriptions, visits, hospitalisations, and laboratory costs. Annual per-patient indirect costs, defined as disease-related loss of earnings, were between $213 and $484, depending on severity. Although no utility studies in CIU were found, one study demonstrated that CIU severely impairs health-related quality of life at the same level as skin conditions, such as psoriasis and atopic dermatitis, on certain dimensions. CONCLUSIONS: This review identified limited evidence on costs, only one economic evaluation, and no utility data for CIU. Lacking comparative data, it is impossible to conclude what the most cost-effective treatment in CIU might be. Due to discrepancies between the cost studies, it is difficult to conclude which cost component contributed the most; however, one study reported that productivity loss was a major component. This review highlighted the substantial cost burden and a humanistic burden, comparable to other skin disorders, of CIU. Further research in this area is needed.

Conference/Value in Health Info

2012-11, ISPOR Europe 2012, Berlin, Germany

Value in Health, Vol. 15, No. 7 (November 2012)

Code

PRS18

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Respiratory-Related Disorders, Sensory System Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×